Tunstall Healthcare Group
Peter Nicklin is an accomplished executive with extensive experience in the pharmaceutical and healthcare industries. Currently, Peter serves as Chairman of the Board at Hansa Biopharma and Healthcare at Home, as well as at Tunstall Healthcare (UK) until July 2024 and previously at Versantis AG until September 2022. Peter held the position of CEO and Member of the Board at Amann Girrbach from June 2017 to January 2020 and worked as a Consultant and Advisor to Pharmaceutical and Med Tech Companies from April 2014 to July 2017. Prior to these roles, Peter held significant leadership positions at Baxter International Inc. as CVP and President for Europe, Middle East, and Africa, and at Bayer HealthCare as a Board Member overseeing strategy and Asia Pacific. Earlier career achievements include roles at Novartis, and Bristol-Myers Squibb, where strategic leadership and market development were key focuses. Peter's academic qualifications include a Bachelor's Degree in Finance and Law from Lancaster University and designation as a Chartered Accountant from ICAEW.
This person is not in any teams
This person is not in any offices
Tunstall Healthcare Group
1 followers
Tunstall is a leading provider of telecare/telehealth solutions. Operating in more than 30 countries and employing over 1,200 people, Tunstall supports 2.5 million people around the world. Tunstall's philosophy is simple - to protect, support and care for people - by providing healthcare technology and services that enable anyonerequiring support and reassurance, such as older people or those with long term needs, to lead an independent life with dignity and reassurance.Tunstall provides complete and fully-integrated telecare and telehealth solutions for home, assisted living and specialist care environments, hospital communication systems, associated support services, response centre software systems and monitoring services.